- Report
- October 2024
- 185 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- October 2024
- 199 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- April 2025
- 194 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- June 2020
- 114 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- January 2024
- 104 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- January 2024
- 73 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
From €117EUR$129USD£101GBP
Linezolid is an antibiotic used to treat a variety of bacterial infections. It is a member of the oxazolidinone class of antibiotics, which inhibit the growth of bacteria by interfering with the production of proteins. Linezolid is effective against both Gram-positive and Gram-negative bacteria, and is used to treat infections such as pneumonia, skin and soft tissue infections, and complicated intra-abdominal infections. It is also used to treat infections caused by multi-drug resistant bacteria. Linezolid is generally well-tolerated, with few side effects.
The Linezolid market is a rapidly growing segment of the antibiotics market. Linezolid is increasingly being used to treat infections caused by multi-drug resistant bacteria, as well as infections that are difficult to treat with other antibiotics. Linezolid is also being used in combination with other antibiotics to treat more serious infections.
Some companies in the Linezolid market include Pfizer, Merck, and Allergan. Show Less Read more